Congenital heart block, sometimes referred to as cardiac neonatal lupus, is a rare but potentially life-threatening condition ...
Immunosuppressive medications. Drugs like corticosteroids or azathioprine work by calming the immune system and reducing the ...
News-Medical.Net on MSN
Rozanolixizumab prevents congenital heart block in high-risk pregnancy
Congenital heart block, sometimes referred to as cardiac neonatal lupus, is a rare but potentially life-threatening condition ...
FACO 2025 presentation highlights HCB101's favorable safety, strong receptor occupancy, and confirmed responses in patients with advanced cancers. TAIPEI, SHANGHAI, and SAN FRANCISCO, Oct. 23, 2025 ...
Gilead Sciences and Arcus Biosciences’ anti-TIGIT antibody domvanalimab has been tied to median overall survival of close to ...
A new antibody therapy strategy that restricts the growth of breast cancer cells could provide a treatment option for the ...
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for serious and rare diseases, today ...
All of the shares to be sold in the underwritten public offering are being offered by Viridian. The offering is expected to close on or about October 23, 2025, subject to customary closing conditions.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback